公衆衛生87巻2号

2023年02月発行

特集 シリーズ 公衆衛生と感染症—感染症に対する医薬品開発と医療の最前線

HIV、結核に対するワクチンの開発の最前線

著者： 岡村智崇¹ 保富康宏¹

所属機関： ¹国立研究開発法人医薬基盤・健康・栄養研究所霊長類医科学研究センター

ページ範囲：P.82 - P.90

ポイント
◆HIVおよび結核の新規ワクチンは、15〜20臨床試験に進んでいる。
◆アジュバント発現弱毒エイズワクチンは、強毒株エイズウイルスを防御する。
◆HPIV2結核ワクチンや組み換えBCGワクチンは、結核菌に対し防御効果を示す。

参考文献

1）Centers for Disease Control（CDC）: Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California. MMWR Morb Mortal Wkly Rep 30: 305-308, 1981

2）IAVI（International AIDS Vaccine Initiative）: https://www.iavi.org/our-science/hiv-vaccines（2022年11月10日閲覧）

3）Flynn NM, et al: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191: 654-665, 2005

4）Rerks-Ngarm S, et al: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220, 2009

5）Zhang P, et al: A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nat Med 27: 2234-2245, 2021

6）Wyand M S, et al: Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus. Nat Med 3: 32-36, 1997

7）Shimizu Y, et al: A genetically engineered live-attenuated simian-human immunodeficiency virus that co-expresses the RANTES gene improves the magnitude of cellular immunity in rhesus macaques. Virology 361: 68-79, 2007

8）Takamura S, et al: Ag85B of mycobacteria elicits effective CTL responses through activation of robust Th1 immunity as a novel adjuvant in DNA vaccine. J Immunol 175: 2541-2547, 2005

9）Okamura T, et al: Long-term protective immunity induced by an adjuvant-containing live-attenuated AIDS virus. NPJ Vaccines 6: 124, 2021

10）WHO: WHO Global Tuberculosis Report 2021.　https://www.who.int/publications/digital/global-tuberculosis-report-2021（2022年11月10日閲覧）

11）Tameris M, et al: Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. Lancet Respir Med 7: 757-770, 2019

12）Aagaard C, et al: A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 17: 189-194, 2011

13）Lin PL, et al: The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest 122: 303-314, 2012

14）Kawano M, et al: Recovery of infectious human parainfluenza type 2 virus from cDNA clones and properties of the defective virus without V-specific cysteine-rich domain. Virology 284: 99-112, 2001

15）Watanabe K, Yasutomi Y, et al: Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization. Vaccine 32: 1727-1735, 2014

16）WHO: Tuberculosis surveillance and monitoring in Europe 2021: 2019 data（2022年11月10日閲覧）

17）Soma S, Yasutomi Y, et al: Primary Role of Suppressor of Cytokine Signaling 1 in Mycobacterium bovis BCG Infection. Infect Immun 86: e00376-18, 2018

18）Mizuno S, Yasutomi Y, et al: SOCS1 Antagonist-Expressing Recombinant Bacillus Calmette-Guérin Enhances Antituberculosis Protection in a Mouse Model. J Immunol 203: 188-197, 2019